Optical Correction and Visual Functions of Adults With Amblyopia
Launched by CENTRE FOR EYE AND VISION RESEARCH · May 26, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how special glasses, or optical correction, can improve vision in adults with a condition called amblyopia, often referred to as "lazy eye." Amblyopia usually develops in childhood and can result in one eye not seeing as well as the other. Researchers want to see if correcting the vision with the right prescription glasses can help improve not just clarity of vision but also other aspects of how the eyes work together. The study will involve various tests to measure changes in visual ability after participants receive their new glasses.
To be eligible for this trial, participants need to be between 18 and 39 years old and have a specific type of amblyopia that meets certain vision criteria. This includes having a significant difference in vision between the two eyes and a need for a new glasses prescription. Those who join the study will have their vision assessed and fitted for appropriate corrective lenses, and they will be monitored to see how their vision improves. This research is important as it could lead to new ways to treat amblyopia in adults and help us understand how the brain can adapt and improve visual functions even later in life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-39 (inclusive) years of age
- • Anisometropic amblyopia (difference of ≥0.50D spherical equivalent or ≥1.50D astigmatism between eyes) or mixed mechanism amblyopia (strabismus and anisometropia)
- • Best corrected visual acuity (BCVA) in the amblyopic eye of 0.3 logMAR to 1.0 logMAR (inclusive)
- • BCVA in the non-amblyopic eye of 0.1 logMAR or better, and an interocular VA difference of 2 logMAR lines or more
- • Difference of 1.00D or more between current refractive correction and study prescription
- • Good general health
- Exclusion Criteria:
- • Other pathological ocular anomalies known to cause reduced visual acuity
- • Presbyopia (based on amplitude of accommodation)
- • Inability to tolerate prescribed refractive correction in spectacles (e.g., due to aniseikonia)
- • Contraindication to cycloplegic eye drops
- • Currently under amblyopia treatment/therapy
- • Inability to comprehend test instructions and/or provide consent
- • Eccentric fixation
- • \>-6.00DS of myopia in either eye with spectacles
- • Bilateral amblyopia
- • Presence of amblyopia that is not due to strabismus and/or anisometropia
- • Presence of (current or previous) psychiatric, visual, or neurological disorders
About Centre For Eye And Vision Research
The Centre for Eye and Vision Research is a leading clinical trial sponsor dedicated to advancing the understanding and treatment of ocular diseases and vision disorders. Committed to innovative research and evidence-based practices, the Centre collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials. By leveraging cutting-edge technologies and interdisciplinary expertise, the Centre aims to enhance patient outcomes and contribute to the development of novel therapies in ophthalmology. Its focus on transparency, ethical standards, and patient safety underscores its mission to improve global eye health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Waterloo, Ontario, Canada
Hong Kong, Guangdong, Hong Kong
Patients applied
Trial Officials
Benjamin Thompson, PhD
Principal Investigator
Centre for Eye and Vision Research Limited
Ken WS Tan, PhD
Study Director
Centre for Eye and Vision Research Limited
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials